Keryx Biopharmaceuticals (KERX) reports that it met primary efficacy points with top-line...

|About: Keryx Biopharmaceuticals,... (KERX)|By:, SA News Editor

Keryx Biopharmaceuticals (KERX) reports that it met primary efficacy points with top-line results from a Phase 3 study of Zerenex for hyposphatemia conducted in Japan with its partner. Shares +16.9% premarket.